BOSTON — A new study out of Brigham and Women’s Hospital shows how newly marketed brand-name drugs in the U.S. are driving up health care spending, resulting in “detrimental effects for patient access and affordability.”
From 2008 to 2021, launch prices for new drugs jumped by more than 20% per year, according to the research from Benjamin Rome and colleagues who studied 548 brand-name drugs.
Also, the percentage of drugs priced above $150,000 per year spiked from 9% in 2008-2013 all the way to 47% in 2020-2021.
